# Pizarra — PT-pseudo_c13fda040310 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c13fda040310
Task: 1

Encounter: Urology - outpatient on 19 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.35 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81674135 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.

Vitals: weight 81 kg, height 180 cm, BMI 25.0, BP 125/95 mmHg, HR 72 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation.

History: Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses.

Patient info: freelance translator; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 5x/week (commuter); IPSS score: 5/35 (mild LUTS).


Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.53 +/- 0.20   (95% CI 0.14-0.90)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=6.1, age=63.0, psad=0.08, dre_ord=0.0, vol=73.0, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (1.35 ng/mL/yr) and the specific PSA history (prior PSA 4.9 ng/mL, 3 months since last PSA) against the PI-RADS 4 score and the prior negative biopsy status. It also missed the context provided by the full mpMRI report, the laboratory panel, and the previous notes, which are crucial for assessing the clinical significance of the rising PSA trajectory.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.53 +/- 0.20). A failure mode is the conflict between the high csPCa predicted probability (0.81674135) and the prior negative biopsy. Another failure mode is the wide aleatoric error ($\text{dA} = 0.17$), suggesting the underlying data distribution is highly heterogeneous for this patient profile. A third failure mode is ignoring the clinical context that the patient is anxious about procedures, which might influence the decision threshold.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features, it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning velocity, it would increase the urgency for further investigation.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial risk assessment or any subtle findings missed in the structured panel.
  <document> laboratory results (full panel) -> This could reveal other markers (e.g., inflammation, diabetes control) that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line—that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_c13fda040310", "radiology_report": "Radiology Division | Catharina Ziekenhuis, Eindhoven | 15 Feb 2025 | Multiparametric MRI Prostate\n\nClinical context: 63-year-old male with escalating PSA trajectory (latest 6.1 ng/mL) and prior negative systematic biopsy. Re-evaluation for targeted sampling.\n\nFINDINGS:\nThe gland measures 73.0 mL in total volume. Within the left mid-gland posterior peripheral zone, a focal lesion (approximately 12 x 9 x 11 mm) demonstrates restricted diffusion alongside early contrast enhancement. T2-weighted sequences show low signal intensity, while high b-value DWI (b=1400) reveals marked hypointensity. Dynamic contrast imaging confirms a focal early enhancement pattern. The transition zone exhibits moderate benign prostatic hyperplasia with cystic degeneration, aligning with the patient\u2019s age and lower urinary tract symptom profile. There is no evidence of extracapsular extension or seminal vesicle invasion. Pelvic lymph nodes appear normal in size and morphology. Skeletal survey shows no suspicious osseous lesions.\n\nIMPRESSION:\nPI-RADS: 4\nprostate volume: 73.0\nPSA density: 0.08\ncsPCa probability: 0.81674135"}

  **psa_trend**
  {"case_id": "PT-pseudo_c13fda040310", "psa_trend": [{"date": "Jun 2023", "val": 1.4}, {"date": "Jan 2024", "val": 2.3}, {"date": "Aug 2024", "val": 3.7}, {"date": "Feb 2025", "val": 6.1}]}

  **previous_notes**
  {"case_id": "PT-pseudo_c13fda040310", "previous_notes": [{"date": "24 Jun 2024", "author": "Dr. E. Mulder (GP)", "text": "A January 2024 assay recorded a PSA of 4.6 ng/mL, marking a continued ascent from the 3.5 ng/mL value noted the previous June. Due to this persistent elevation coupled with mild lower urinary tract symptoms, a systematic transrectal ultrasound-guided biopsy was carried out in June 2024. Histological analysis returned entirely benign, with no signs of malignancy."}, {"date": "29 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "An initial screening measurement in June 2023 yielded 3.5 ng/mL. The individual experiences occasional nocturia and a diminished urinary stream, which have been addressed through conservative measures. Given his age alongside this borderline elevation, an assessment was initiated at the urology outpatient clinic to facilitate comprehensive risk stratification and further investigation."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_c13fda040310", "laboratory_results": [{"name": "PSA", "val": "6.1 ng/mL", "date": "04 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.30 ng/mL", "date": "04 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "04 Feb 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.1 g/dL", "date": "04 Feb 2025", "flag": ""}, {"name": "WBC", "val": "5.5 x10^9/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "201 x10^9/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "98 umol/L", "date": "04 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "04 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "11.3 nmol/L", "date": "04 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "74 U/L", "date": "04 Feb 2025", "flag": ""}, {"name": "LDH", "val": "226 U/L", "date": "04 Feb 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS score: 4
  - Focal lesion (12 x 9 x 11 mm) with restricted diffusion and early contrast enhancement in the peripheral zone.
  - PSA velocity: 1.35 ng/mL/yr, showing a significant rise from 3.7 ng/mL (Aug 2024) to 6.1 ng/mL (Feb 2025).
  - csPCa predicted probability: 0.81674135

  AGAINST sampling this patient now:
  - Prior biopsy: Negative
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Previous biopsy result: Entirely benign

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the PI-RADS 4 finding and the concerning PSA velocity, which contradicts the prior negative biopsy result. This leans towards a strong recommendation for further investigation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to a PI-RADS 4 lesion with restricted diffusion and a concerning PSA velocity of 1.35 ng/mL/yr, which contradicts the prior negative biopsy. The PI-RADS 4 score and the rising PSA trajectory are decisive factors, overriding the prior negative result. The statistical prior suggested biopsy, and the retrieved evidence confirms this direction.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
